Variant Bio is an early stage, Lux-backed, genomics-based drug development company leveraging insights derived from studying outlier populations to discover new medicines.

Andrew Farnum comes to Variant from The Bill & Melinda Gates Foundation where he spent the last eight years running global investments responsible for what is now a $2 billion impact investing vehicle focused on the global healthcare objectives.

In Farnum, Variant has captured a leader with a global perspective as well as a true desire to further the betterment of mankind. Andrew is also a talented investment executive, and somebody who has learned how to manage smaller organizations.

In summary, Farnum possesses charisma, perspective, intellectual curiosity, an elevated ethical posture, and knowledge of the venture world, assets that will serve him and Variant well as the organization seeks to execute on its global mission of discovering novel therapeutics to address major unmet medical needs of patients across the world.